Skip to main content
Premium Trial:

Request an Annual Quote

Karius Inks Deal to Launch Infectious Disease Test in Brazil

NEW YORK (GenomeWeb) — Karius announced today that it has signed an agreement to launch its next-generation sequencing-based infectious disease test in Brazil with medical diagnostics firm Dasa.

The recently launched test can detect over 1,000 pathogens — including bacteria, DNA viruses, fungi, mold, and protozoa — from microbial cell-free DNA in a single blood draw.

Under the terms of the deal, São Paulo-based Dasa will offer the test to hospitals in Brazil. Specimen samples from local reference laboratories in Brazil will be processed and reported at Karius' CLIA laboratory in Redwood City, California. Results are expected to be available within 48 after after samples are received.

Additional terms were not disclosed.

"Bringing the Karius test to Brazil is the first step we’re taking to make the Karius technology available to patients worldwide," Karius CEO Mickey Kertesz said in a statement.

Earlier this month, Karius' clinical collaborators presented interim study results and anecdotal evidence related to their use of the Stanford University spinout's test.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.